Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Stopped early · Phase 2 · Has a placebo group

Conditions studied: NSCLC (Non-small Cell Lung Carcinoma)

In brief

The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.

Key facts

Study ID

NCT02119650

Run by

Incyte Corporation

People needed

76

Starts

2014-02-11

Expected to finish

2016-06-21

Last updated by the study team

2018-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).
• Radiographically measurable or evaluable disease.
• Life expectancy of at least 12 weeks.
• Tumor without activating driver mutations for which there is available therapy (eg, tumor without mutations in epidermal growth factor receptor or anaplastic lymphoma).
• An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:
• Criteria:
• C-reactive protein >10 mg/L AND albumin ≥35 g/L; Score = 1
• C-reactive protein >10 mg L AND albumin <35 g/L; Score = 2
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified laboratory parameters at the screening visit.

You may not qualify if…

• Squamous or mixed histology (eg, adenosquamous) NSCLC
• Previous systemic therapy for advanced or metastatic disease.
• Known active central nervous system (CNS) metastases.
• Current or previous other malignancy within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval.
• Current uncontrolled cardiac disease such as angina or myocardial infarction, congestive heart failure including New York Heart Association functional classification of 3, or arrhythmia requiring treatment.
• Uncontrolled concomitant medical conditions, including, but not limited to, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric diseases.

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Fayetteville, Arkansas, United States
• Study site — Fresno, California, United States
• Study site — La Jolla, California, United States
• Study site — San Diego, California, United States
• Study site — San Francisco, California, United States
• Study site — Lone Tree, Colorado, United States
• Study site — Norwich, Connecticut, United States
• Study site — Southington, Connecticut, United States
• Study site — Augusta, Georgia, United States
• Study site — Joliet, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Lafayette, Indiana, United States
• Study site — Kansas City, Kansas, United States
• Study site — Detroit, Michigan, United States
• Study site — St Louis, Missouri, United States
• Study site — Reno, Nevada, United States
• Study site — Lebanon, New Hampshire, United States
• Study site — Mount Kisco, New York, United States
• Study site — New York, New York, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Canton, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Chattanooga, Tennessee, United States
• Study site — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.